In 2017, Proteus Health and Otsuka partnered to bring an augmentation digital therapeutic form of the drug Abilify through FDA approval. Called Abilify MyCite, the drug monitors the drug adherence therapeutic regimen of the drug through radio frequency identification (RFID) sensors contained within the pill capsule that are tracked via a chest-worn patch. The device received significant media attention, both for proposed improvement of clinical outcomes and high costs ($1,650/month of treatment in contrast to $940 without the sensor). While a partnership was formed in late 2018 with Magellen Health for a limited release in order to assess impact, there has yet to be any movement on that front, or any commercial adoption of the technology.
Contact us to learn the benefits of becoming a Lux member.
Or call us now
For North America (Boston Headquarters)
+1 (617) 502-5300
For EMEA (Amsterdam)
+31 20 280 7900
For APAC (Singapore)